IMMvention Therapeutix is developing first-in-class Bach1 inhibitors as oral therapies for patients with sickle cell disease and other inflammatory conditions. These small molecule pan-inflammasome inhibitors aim to reduce inflammation and improve patient outcomes in chronic inflammatory diseases.
Funding
$41.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Sickle cell disease and other chronic inflammatory conditions often lead to significant inflammation and limited treatment options, especially for patients lacking access to gene therapies. Current treatments may not effectively address the underlying inflammatory mechanisms, resulting in suboptimal patient outcomes.
Solution
IMMvention Therapeutix is developing first-in-class, orally available Bach1 inhibitors to treat sickle cell disease and other inflammatory conditions. Their small molecule pan-inflammasome inhibitors, such as IMM-4800, aim to reduce inflammation by targeting the Bach1 protein, a key regulator of the inflammatory response. IMM-4800 exhibits exceptional drug-like properties, differentiating it from other Bach1 inhibitors. The company's lead program, IMM-004, is progressing towards IND enabling studies and Phase 1 clinical trials, with the goal of providing a globally accessible therapy for patients.
Target Audience
The primary target audience includes patients with sickle cell disease and other chronic inflammatory conditions, as well as pharmaceutical companies interested in partnering for further development and commercialization.
Features
- Orally available Bach1 inhibitors for systemic treatment of inflammatory diseases
- IMM-4800: A lead compound with differentiated drug-like properties
- Pan-inflammasome inhibition to reduce inflammation in sickle cell disease
- Pipeline programs targeting other chronic non-CNS and neurodegenerative diseases
- IND enabling studies and Phase 1 clinical trials planned for lead program IMM-004